Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mygotes
- Development stage
- Preclinical
- Lead developer
- MygoGenesis
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Mygotes are laboratory-produced, autologous, embryonic-like developmental-state cells generated from patient-derived somatic cells using a proprietary, non-genetic reprogramming method called the Mygotic Process. Unlike induced pluripotent stem cells (iPSCs), which require genetic or viral reprogramming, Mygotes are produced without viral vectors or transcription-factor engineering, reverting somatic cells to a highly plastic, totipotent-like state with globally demethylated DNA and two pronuclei. Developed by MygoGenesis, Mygotes are designed to serve as a natural, potent, and scalable cellular foundation for applications in regenerative medicine, cell therapy, tissue engineering, and biomanufacturing.
- Other names
- autologous embryonic-like developmental-state cellsautologous totipotent cells
Beyond the preview
Go deeper on Mygotes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mygotes.